Although the minds behind scientific research are creating more innovative solutions than ever, the cost of developing these discoveries into products for patients is extremely high. The average outlay for bringing a new drug to market is around US$2.8 billion, over a development timeline of 12 years, but these factors still only lead to a 10% approval rating from regulators. This is a clear sign that the industry urgently needs to find solutions which can make drug discovery more cost-effective and efficient, while still maintaining the same rigorous levels of quality control.
Read on to discover the extent of these issues, as well as how events like CPHI Milan can help the pharmaceutical sector address these timely concerns about the state of R&D spending.


